Clinical trial
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's…
NCT00496431 · Italfarmaco, Industry · Terminated
Key facts
| NCT number | NCT00496431 |
|---|---|
| Title | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients |
| Official title | Phase II Study of the Histone-deacetylase Inhibitor ITF2357 in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients |
| Lead sponsor | Italfarmaco, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | histone deacetylase inhibitor (ITF2357) |
| Enrollment | 19 |
| Start date | May 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Jan 27, 2022 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: